175 related articles for article (PubMed ID: 25006835)
1. Comparison of Intracellular Stress Response of NCI-H526 Small Cell Lung Cancer (SCLC) Cells to Platinum(II) Cisplatin and Platinum(IV) Oxoplatin.
Hamilton G
Cancers (Basel); 2014 Jul; 6(3):1487-99. PubMed ID: 25006835
[TBL] [Abstract][Full Text] [Related]
2. Comparison of the effects of the oral anticancer platinum(IV) complexes oxoplatin and metabolite cis-diammine-tetrachlorido-platinum(IV) on global gene expression of NCI-H526 cells.
Olszewski U; Ulsperger E; Geissler K; Hamilton G
J Exp Pharmacol; 2011; 3():43-50. PubMed ID: 27186109
[TBL] [Abstract][Full Text] [Related]
3. In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.
Olszewski U; Ach F; Ulsperger E; Baumgartner G; Zeillinger R; Bednarski P; Hamilton G
Met Based Drugs; 2009; 2009():348916. PubMed ID: 19587824
[TBL] [Abstract][Full Text] [Related]
4. Alterations of phosphoproteins in NCI-H526 small cell lung cancer cells involved in cytotoxicity of cisplatin and titanocene Y.
Olszewski U; Deally A; Tacke M; Hamilton G
Neoplasia; 2012 Sep; 14(9):813-22. PubMed ID: 23019413
[TBL] [Abstract][Full Text] [Related]
5. In vitro Cytotoxic Activities of the Oral Platinum(IV) Prodrug Oxoplatin and HSP90 Inhibitor Ganetespib against a Panel of Gastric Cancer Cell Lines.
Klameth L; Rath B; Hamilton G
J Cancer; 2017; 8(10):1733-1743. PubMed ID: 28819369
[TBL] [Abstract][Full Text] [Related]
6. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents.
Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ
Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657
[TBL] [Abstract][Full Text] [Related]
7. DNA interactions of antitumor platinum(IV) complexes.
Nováková O; Vrána O; Kiseleva VI; Brabec V
Eur J Biochem; 1995 Mar; 228(3):616-24. PubMed ID: 7737155
[TBL] [Abstract][Full Text] [Related]
8. In vitro cytotoxicity of combinations of dichloroacetate with anticancer platinum compounds.
Olszewski U; Poulsen TT; Ulsperger E; Poulsen HS; Geissler K; Hamilton G
Clin Pharmacol; 2010; 2():177-83. PubMed ID: 22291503
[TBL] [Abstract][Full Text] [Related]
9. Regulation of platinum-compound cytotoxicity by the c-Jun N-terminal kinase and c-Jun signaling pathway in small-cell lung cancer cells.
Levresse V; Marek L; Blumberg D; Heasley LE
Mol Pharmacol; 2002 Sep; 62(3):689-97. PubMed ID: 12181446
[TBL] [Abstract][Full Text] [Related]
10. Anticancer activity and mode of action of titanocene C.
Olszewski U; Claffey J; Hogan M; Tacke M; Zeillinger R; Bednarski PJ; Hamilton G
Invest New Drugs; 2011 Aug; 29(4):607-14. PubMed ID: 20162321
[TBL] [Abstract][Full Text] [Related]
11. Cycloplatam and oxoplatin--the new antitumor platinum compounds of the second generation.
Presnov MA; Konovalova AL
Arch Geschwulstforsch; 1988; 58(1):43-9. PubMed ID: 3285804
[TBL] [Abstract][Full Text] [Related]
12. Complexes of oxoplatin with rhein and ferulic acid ligands as platinum(iv) prodrugs with high anti-tumor activity.
Tan MX; Wang ZF; Qin QP; Zou BQ; Liang H
Dalton Trans; 2020 Feb; 49(5):1613-1619. PubMed ID: 31942585
[TBL] [Abstract][Full Text] [Related]
13. Picoplatin overcomes resistance to cell toxicity in small-cell lung cancer cells previously treated with cisplatin and carboplatin.
Tang CH; Parham C; Shocron E; McMahon G; Patel N
Cancer Chemother Pharmacol; 2011 Jun; 67(6):1389-400. PubMed ID: 20809122
[TBL] [Abstract][Full Text] [Related]
14. A sensitive postcolumn derivatization/UV detection system for HPLC determination of antitumor divalent and quadrivalent platinum complexes.
Kizu R; Yamamoto T; Yokoyama T; Tanaka M; Miyazaki M
Chem Pharm Bull (Tokyo); 1995 Jan; 43(1):108-14. PubMed ID: 7895301
[TBL] [Abstract][Full Text] [Related]
15. A Ratiometric Fluorescent Probe for Cisplatin: Investigating the Intracellular Reduction of Platinum(IV) Prodrug Complexes.
Ong JX; Lim CSQ; Le HV; Ang WH
Angew Chem Int Ed Engl; 2019 Jan; 58(1):164-167. PubMed ID: 30407697
[TBL] [Abstract][Full Text] [Related]
16. [Pharmacological approach to the platinum compounds].
Sasaki Y
Gan To Kagaku Ryoho; 1992 Apr; 19(4):456-62. PubMed ID: 1313667
[TBL] [Abstract][Full Text] [Related]
17. DNA damage and repair in human lymphocytes exposed to three anticancer platinum drugs.
Blasiak J; Kowalik J; Małecka-Panas E; Drzewoski J; Wojewódzka M
Teratog Carcinog Mutagen; 2000; 20(3):119-31. PubMed ID: 10820422
[TBL] [Abstract][Full Text] [Related]
18. The influence of tumour microenvironmental factors on the efficacy of cisplatin and novel platinum(IV) complexes.
Mellor HR; Snelling S; Hall MD; Modok S; Jaffar M; Hambley TW; Callaghan R
Biochem Pharmacol; 2005 Oct; 70(8):1137-46. PubMed ID: 16139250
[TBL] [Abstract][Full Text] [Related]
19. SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.
Abrams TJ; Lee LB; Murray LJ; Pryer NK; Cherrington JM
Mol Cancer Ther; 2003 May; 2(5):471-8. PubMed ID: 12748309
[TBL] [Abstract][Full Text] [Related]
20. Prediction of the antitumor activity of new platinum analogs based on their ex vivo pharmacodynamics as determined by bioassay.
Sasaki Y; Shinkai T; Eguchi K; Tamura T; Ohe Y; Ohmori T; Saijo N
Cancer Chemother Pharmacol; 1991; 27(4):263-70. PubMed ID: 1847845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
